AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer
AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.
How this was made
The 30-second read
Why it matters
The policy aligns reimbursement across MAC jurisdictions, potentially increasing procedure volumes for eligible prostate and liver cancer patients.
Market read
First report of expanded Medicare Advantage coverage for NanoKnife, likely supportive for ANGO's valuation.
What to watch
Potential delays in provider adoption and competition from thermal ablation technologies.
Background
Humana, a major Medicare Advantage insurer, updated its policy to apply LCD L40205 criteria for AngioDynamics' NanoKnife IRE system.
Ticker impact
Humana added coverage for AngioDynamics' NanoKnife IRE for prostate and liver cancer, expanding reimbursement.
potential upward pressure as market prices in broader reimbursement.
Reimbursement policy changes directly affect revenue potential; investors typically react positively to expanded Medicare coverage.
Market effects
May boost other IRE and minimally invasive oncology device makers.
U.S. Medicare Advantage market sees increased utilization of NanoKnife.
Limited to U.S. insurers; minimal global ripple.
Counterpoint
If utilization is low or CMS reverses policy, the upside could be muted.
Key entities
- CompanyAngioDynamics, Inc.
Medical technology firm offering the NanoKnife IRE system.
- InsurerHumana
Large Medicare Advantage insurer providing coverage policy.
